Title
Category
Credits
Event date
Cost
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo.
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc.
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored.
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that cardiologists, who are tasked with managing a patient population with chronic cardiovascular disease (CVD) that is, resultantly, at high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to maintain effective CVD disease management while also keeping their patients safe.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients.
  • Oncology
  • ACPE Pharmacy
  • Participation
$0.00
Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca.
  • Psychiatry
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The rapid onset of COVID-19 in the United States, combined with the dismantling of the spring 2020 medical conference infrastructure and widespread travel bans and social distancing has created a synchronous need in all clinical arenas to manage patients with pre-existing conditions, such as schizophrenia, who require management with LAIs. Join our expert faculty for this on-demand online activity, focusing on their expert insights into guiding patients, caregivers, and clinicians on using LAIs during the global health pandemic of COVID-19.
  • Psychiatry
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
​​​​​​Join Drs Les Citrome, Steve Stoner, and Board Certified Family Psychiatric Nurse Practitioner Tory Woodward for this on-demand online activity, as they discuss considerations for implementing LAI clinics and best practices for communicating with patients, caregivers, and clinicians regarding the use of LAIs during the global health pandemic of COVID-19.  This activity is supported by an educational grant from Alkermes.
  • Psychiatry
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
In recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality. Also, much evidence suggests the use of these treatments should no longer be reserved for last line, but offered at an earlier place in the illness. Moreover, new agents have arrived on the market which can be dosed without oral overlap, paving the way to less burdensome initiation strategies. Join Drs.

Pages